Pfizer feels invulnerable
Pfizer shareholders approve motion to replace current "classified" board structure (directors serving staggered three-year terms) with annual election of all directors April 24. Pfizer CEO Henry McKinnell explains that annual election of all directors is in keeping with the principle that "directors should be responsive to the shareholder group. If the directors do something the shareholders don't like, the shareholders should be able to kick us bums out, quite frankly." The classified board structure was set up by Pfizer decades ago to provide a degree of protection against hostile takeovers, McKinnell notes, to head off the possibility that a competing board "might be nominated and elected by the opposing company." However, "in this present day and age, as the third most valuable company in the world, there quite frankly is nobody who could launch a hostile takeover bid against Pfizer"...
You may also be interested in...
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.
The company is optimistic about a significant portion of eligible patients opting for its newly approved long-acting HIV therapy over daily, oral antiviral therapy.